Tue, Jul 22, 2014, 9:54 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Mast Therapeutics, Inc. Message Board

  • mentalalchemist mentalalchemist Aug 20, 2013 7:51 AM Flag

    Q3 Positive Data from tQT/QTc Study soon to be released.

    Here is your sneak peak... Short Squeeze coming soon...

    Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study.

    Cheung AT, Chan MS, Ramanujam S, Rangaswami A, Curl K, Franklin P, Wun T.

    Source

    Departmentsof Pathology and Laboratory Medicine, UC Davis School of Medicine, Davis, CA, USA. atcheung@ucdavis.edu

    Abstract

    Nine patients with sickle cell disease (SCD) who were hospitalized at UC Davis Medical Center for vaso-occlusive crisis (VOC) were studied as part of a randomized double-blind phase III clinical trial to investigate the real-time effects of poloxamer 188 on VOC. All patients showed significant microvascular changes from normal (steady-state) values during VOC (diminished venular diameter and red cell velocity). The patients were randomly assigned to be treated with poloxamer 188 or placebo. Poloxamer 188 (n = 4) but not placebo (n = 5) significantly reversed these microvascular changes approximately 2 hours postinitiation of loading infusion (100 mg/kg in 1 hour). Further significant improvement induced by poloxamer 188 but not placebo was observed or = 7 hours postinfusion, resulting in a significant reversal of the microvascular changes to steady-state values.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MSTX
0.60+0.02(+3.09%)Jul 22 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.